Unveiling Specific Triggers and Precipitating Factors for Fatal Cardiac Events in Inherited Arrhythmia Syndromes

Circulation Journal

Volumn 79, Issue 6, 2015, Pages 1185-1192

  Nakajima, Tadashi ^a   Kaneko, Yoshiaki ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fatal arrhythmias; Genes; Mutations; Precipitating factors; Triggers

Indexed keywords

A KINASE ANCHOR PROTEIN 9; ANKYRIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL VOLTAGE DEPENDENT L TYPE ALPHA 1C SUBUNIT; CALMODULIN; CALSEQUESTRIN 2 PROTEIN; CAVEOLIN 3; GLYCEROL 3 PHOSPHATE DEHYDROGENASE 1 LIKE PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; KIR 3.4 PROTEIN; KV4.3 PROTEIN; MIRP2 PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNE2; POTASSIUM CHANNEL KCNQ1; PROTEIN; RYANODINE RECEPTOR; SODIUM CHANNEL NAV1.5; SUR2A PROTEIN; SYNTROPHIN ALPHA 1; TRIADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE DEPENDENT L TYPE CALCIUM CHANNEL SUBUNIT BETA 1 PROTEIN; VOLTAGE GATED CALCIUM CHANNEL SUBUNIT ALPHA 2D PROTEIN; VOLTAGE GATED SODIUM CHANNEL BETA 1 SUBUNIT; VOLTAGE GATED SODIUM CHANNEL BETA 3 SUBUNIT; VOLTAGE GATED SODIUM CHANNEL BETA 4 SUBUNIT; ION CHANNEL;

ACUTE CORONARY SYNDROME; BRADYCARDIA; BRUGADA SYNDROME; CARDIAC MEMORY; CARDIOVASCULAR PARAMETERS; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; EARLY REPOLARIZATION SYNDROME; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; FATALITY; FEVER; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HUMAN; HYPOKALEMIA; ION CURRENT; LONG QT SYNDROME; REVIEW; RISK FACTOR; TAKOTSUBO CARDIOMYOPATHY; TORSADE DES POINTES; COMPLICATION; DEATH, SUDDEN, CARDIAC; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MENTAL STRESS; METABOLIC DISORDER; MORTALITY; PHENOTYPE; PHYSIOLOGICAL STRESS; PHYSIOLOGY; RISK ASSESSMENT; SYNDROME;

ACUTE CORONARY SYNDROME; ARRHYTHMIAS, CARDIAC; BRADYCARDIA; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ION CHANNELS; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL; SYNDROME; TAKOTSUBO CARDIOMYOPATHY; WATER-ELECTROLYTE IMBALANCE;

EID: 84930074617     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0322     Document Type: Review

References (78)

1. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12: 17 - 23.
2. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795 - 803.
3. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805 - 811.
4. Shimizu W. Update of diagnosis and management of inherited cardiac arrhythmias. Circ J 2013; 77: 2867 - 2872.
5. Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AA. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013; 62: 169 - 180.
6. Mizusawa Y, Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome. Circ J 2014; 78: 2827 - 2833.
7. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996; 384: 80 - 83.
8. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299 - 307.
9. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89 - 95.
10. Wilde AA, Jongbloed RJ, Doevendans PA, Duren DR, Hauer RN, van Langen IM, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1related patients (LQTS1). J Am Coll Cardiol 1999; 33: 327 - 332.
11. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007; 49: 1092 - 1098.
12. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, et al. High efficacy of β-blockers in long-QT syndrome type 1: Contribution of noncompliance and QT-prolonging drugs to the occurrence of β-blocker treatment “failures”. Circulation 2009; 119: 215 - 221.
13. Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 2014; 64: 1352 - 1358.
14. Calvillo L, Spazzolini C, Vullo E, Insolia R, Crotti L, Schwartz PJ. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: Implications for the clinical management of LQT3 patients. Heart Rhythm 2014; 11: 126 - 132.
15. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007; 116: 1137 - 1144.
16. Bos JM, Bos KM, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation in long QT syndrome: Analysis of therapeutic nonresponders. Circ Arrhythm Electrophysiol 2013; 6: 705 - 711.
17. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992; 20: 1391 - 1396.
18. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with STsegment elevation. Circulation 1999; 100: 1660 - 1666.
19. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293 - 296.
20. Antzelevitch C. Genetic, molecular and cellular mechanisms underlying the J wave syndromes. Circ J 2012; 76: 1054 - 1065.
21. Nakajima T, Wu J, Kaneko Y, Ashihara T, Ohno S, Irie T, et al. KCNE3 T4A as the genetic basis of Brugada-pattern electrocardiogram. Circ J 2012; 76: 2763 - 2772.
22. Cerrone MPriori SG., Genetics of sudden death: Focus on inherited channelopathies. Eur Heart J 2011; 32: 2109 - 2118.
23. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110: 1731 - 1737.
24. Aizawa Y, Yamakawa H, Takatsuki S, Katsumata Y, Nishiyama T, Kimura T, et al. Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation. Int J Cardiol 2013; 168: 5083 - 5085.
25. Shinohara T, Ebata Y, Ayabe R, Fukui A, Okada N, Yufu K, et al. Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. Heart Rhythm 2014; 11: 1441 - 1445.
26. Mahida S, Derval N, Sacher F, Berte B, Yamashita S, Hooks DA, et al. History and clinical significance of early repolarization syndrome. Heart Rhythm 2015; 12: 242 - 249.
27. Haissaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008; 358: 2016 - 2023.
28. Kaneko Y, Horie M, Niwano S, Kusano KF, Takatsuki S, Kurita T, et al. Electrical storm in patients with brugada syndrome is associated with early repolarization. Circ Arrhythm Electrophysiol 2014; 7: 1122 - 1128.
29. Haissaguerre M, Sacher F, Nogami A, Komiya N, Bernard A, Probst V, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol 2009; 53: 612 - 619.
30. Katsuumi G, Shimizu W, Watanabe H, Noda T, Nogami A, Ohkubo K, et al. Efficacy of bepridil to prevent ventricular fibrillation in severe form of early repolarization syndrome. Int J Cardiol 2014; 172: 519 - 522.
31. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Cat echolaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512 - 1519.
32. Leenhardt A, Denjoy I, Guicheney P. Catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2012; 5: 1044 - 1052.
33. Kawamura M, Ohno S, Naiki N, Nagaoka I, Dochi K, Wang Q, et al. Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan. Circ J 2013; 77: 1705 - 1713.
34. Nyegaard M, Overgaard MT, Sondergaard MT, Vranas M, Behr ER, Hildebrandt LL, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet 2012; 91: 703 - 712.
35. Crotti L, Johnson CN, Graf E, De Ferrari GM, Cuneo BF, Ovadia M, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 2013; 127: 1009 - 1017.
36. Nakajima T, Kaneko Y, Taniguchi Y, Hayashi K, Takizawa T, Suzuki T, et al. The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization. Eur Heart J 1997; 18: 530 - 531.
37. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380 - 383.
38. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625 - 1633.
39. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97: 10613 - 10618.
40. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drugassociated torsades de pointes. Circulation 2002; 105: 1943 - 1948.
41. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007; 4: 603 - 607.
42. Itoh H, Sakaguchi T, Ding WG, Watanabe E, Watanabe I, Nishio Y, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol 2009; 2: 511 - 523.
43. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012; 5: 91 - 99.
44. Petersen CI, McFarland TR, Stepanovic SZ, Yang P, Reiner DJ, Hayashi K, et al. In vivo identification of genes that modify ether-ago-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci USA 2004; 101: 11773 - 11778.
45. Nakajima T, Hayashi K, Viswanathan PC, Kim MY, Anghelescu M, Barksdale KA, et al. HERG is protected from pharmacological block by α-1,2-glucosyltransferase function. J Biol Chem 2007; 282: 5506 - 5513.
46. Hayashi K, Fujino N, Ino H, Uchiyama K, Sakata K, Konno T, et al. A KCR1 variant implicated in susceptibility to the long QT syndrome. J Mol Cell Cardiol 2011; 50: 50 - 57.
47. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012; 60: 841 - 850.
48. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www. brugadadrugs.org). Heart Rhythm 2009; 6: 1335 - 1341.
49. Chevalier P, Bellocq C, Millat G, Piqueras E, Potet F, Schott JJ, et al. Torsades de pointes complicating atrioventricular block: Evidence for a genetic predisposition. Heart Rhythm 2007; 4: 170 - 174.
50. Subbiah RN, Gollob MH, Gula LJ, Davies RW, Leong-Sit P, Skanes AC, et al. Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates. Can J Cardiol 2010; 26: 208 - 212.
51. Oka Y, Itoh H, Ding WG, Shimizu W, Makiyama T, Ohno S, et al. Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome. Circ J 2010; 74: 2562 - 2571.
52. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87: 1012 - 1018.
53. + current in cardiac cells. Circ Res 1997; 80: 782 - 789.
54. + concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 2009; 119: 2745 - 2757.
55. Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: Long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42: 1777 - 1782.
56. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med 2008; 149: 216 - 218.
57. Samani K, Wu G, Ai T, Shuraih M, Mathuria NS, Li Z, et al. A novel SCN5A mutation V1340I in Brugada syndrome augmenting arrhythmias during febrile illness. Heart Rhythm 2009; 6: 1318 - 1326.
58. Keller DI, Huang H, Zhao J, Frank R, Suarez V, Delacretaz E, et al. A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation. Cardiovasc Res 2006; 70: 521 - 529.
59. Amin AS, Klemens CA, Verkerk AO, Meregalli PG, Asghari Roodsari A, de Bakker JM, et al. Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J 2010; 18: 165 - 169.
60. Amin AS, Herfst LJ, Delisle BP, Klemens CA, Rook MB, Bezzina CR, et al. Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest 2008; 118: 2552 - 2561.
61. Shibata R, Ashizawa N, Komiya N, Fukae S, Nakao K, Seto S, et al. Torsade de pointes triggered by high fever in patient with LQT2 syndrome. J Jpn Soc Intern Med 2009; 98: 1996 - 1998 (in Japanese).
62. Zhao JT, Hill AP, Varghese A, Cooper AA, Swan H, Laitinen Forsblom PJ, et al. Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype. J Cardiovasc Electrophysiol 2009; 20: 923 - 930.
63. Tange T, Imai M, Ui G, Kogure S, Ono Y, Kobayashi N, et al. TdP developed in a fever opportunity, once had a diagnosis of druginduced LQT 7 years ago, showing KCNH2 mutant: A case report. Ther Res 2012; 33: 1639 - 1642 (in Japanese).
64. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996; 379: 833 - 836.
65. Nakajima T, Furukawa T, Tanaka T, Katayama Y, Nagai R, Nakamura Y, et al. Novel mechanism of HERG current suppression in LQT2: Shift in voltage dependence of HERG inactivation. Circ Res 1998; 83: 415 - 422.
66. Hu D, Viskin S, Oliva A, Carrier T, Cordeiro JM, Barajas-Martinez H, et al. Novel mutation in the SCN5A gene associated with arrhyth mic storm development during acute myocardial infarction. Heart Rhythm 2007; 4: 1072 - 1080.
67. γ-ketoaldehyde scavengers protect NaV1.5 from oxidant-induced inactivation. J Mol Cell Cardiol 2010; 48: 352 - 359.
68. Halkin A, Roth A, Lurie I, Fish R, Belhassen B, Viskin S. Pausedependent torsade de pointes following acute myocardial infarction: A variant of the acquired long QT syndrome. J Am Coll Cardiol 2001; 38: 1168 - 1174.
69. Crotti L, Hu D, Barajas-Martinez H, De Ferrari GM, Oliva A, Insolia R, et al. Torsades de pointes following acute myocardial infarction: Evidence for a deadly link with a common genetic variant. Heart Rhythm 2012; 9: 1104 - 1112.
70. Nakajima T, Kaneko Y, Saito A, Irie T, Kato T, Iso T, et al. Post myocardial ischemia-associated torsades de pointes in a patient carrying a KCNQ1 G643S variant. Intern Med 2010; 49: 2587 - 2591.
71. Kubota T, Horie M, Takano M, Yoshida H, Takenaka K, Watanabe E, et al. Evidence for a single nucleotide polymorphism in the KCNQ1 potassium channel that underlies susceptibility to life-threatening arrhythmias. J Cardiovasc Electrophysiol 2001; 12: 1223 - 1229.
72. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78: 1479 - 1487.
73. Jiang M, Cabo C, Yao J, Boyden PA, Tseng G. Delayed rectifier K currents have reduced amplitudes and altered kinetics in myocytes from infarcted canine ventricle. Cardiovasc Res 2000; 48: 34 - 43.
74. Yoshikawa T. Takotsubo cardiomyopathy, a new concept of cardiomyopathy: Clinical features and pathophysiology. Int J Cardiol 2014; 182: 297 - 303.
75. Madias C, Fitzgibbons TP, Alsheikh-Ali AA, Bouchard JL, Kalsmith B, Garlitski AC, et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm 2011; 8: 555 - 561.
76. Grilo LS, Pruvot E, Grobety M, Castella V, Fellmann F, Abriel H. Takotsubo cardiomyopathy and congenital long QT syndrome in a patient with a novel duplication in the Per-Arnt-Sim (PAS) domain of hERG1. Heart Rhythm 2010; 7: 260 - 265.
77. Jeyaraj D, Ashwath M, Rosenbaum DS. Pathophysiology and clinical implications of cardiac memory. Pacing Clin Electrophysiol 2010; 33: 346 - 352.
78. Di Cori A, Zucchelli G, Romano S, Bongiorni MG. Proarrhythmic effect of pacing mode reprogramation in a patient with a congenital long-QT syndrome. J Cardiovasc Electrophysiol 2013; 24: 1304 - 1305.